Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Imovane: Best Online Pharmacy
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination.
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
Dimethyl fumarate (BG-12, Tecfidera) - NICE gives initial "no" decision
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Alemtuzumab for the Treatment of Multiple Sclerosis
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Alemtuzumab and multiple sclerosis: therapeutic application.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.

Pages